Regeneron: Positive Interim Data From COVID-19 Trial


Regeneron Pharmaceuticals has reported positive initial results from an ongoing Phase III clinical trial of antibody cocktail REGEN-COV used as a passive vaccine for preventing Covid-19 in people at high risk of infection.


REGEN-COV is a cocktail of two monoclonal antibodies, namely casirivimab and imdevimab (also known as REGN10933 and REGN10987), and can specifically inhibit SARS-CoV-2 infectivity.


Check out the full article right here.

0 comments

© 2021 by Covid Plasma Initiative Foundation

The Yitzchok Lebovits COVID Plasma Initiative is dedicated in memory of R’ Yitzchok a"h Ben R’ Moshe Eliezer y"blt, who recently passed away. R' Yitzchok was a brother of Chaim Lebovits who has been a driving force behind every aspect of this initiative to bring this life-saving therapy to the people who need it.